TY - THES A1 - Shaikh, Muhammad Haroon T1 - Nicht-hämatopoetische lymphoide Stromazellen aktivieren alloreaktive CD4\(^+\) T-Zellen in der Initiierung der akuten Graft-versus-Host Disease T1 - Non-hematopoietic lymphoid stromal cells prime alloreactive CD4\(^+\) T cells during acute graft-versus-host disease N2 - In der Initiationsphase der akuten Graft-versus-Host Erkrankung (GvHD) werden CD4+ T-Zellen in den lymphatischen Organen durch hämatopoietische Antigen-präsentierende Zellen aktiviert. Im Gegensatz dazu, werden in der Effektorphase CD4+ T-Zellen von nicht-hämatopoetischen Zellen im Dünndarm aktiviert. Wir stellten die Hypothese auf, dass alloreaktive CD4+ T-Zellen nach allogener hämatopoetischer Zelltransplantation, welche in der Initiationsphase der aGvHD vorwiegend in die sekundären lymphatischen Organe migrieren, dort durch nicht-hämatopoetische Lymphknoten-Stromazellen über die Erkennung von MHC-Klasse II aktiviert werden. Um diese Hypothese zu testen, setzten wir ein von allogenen CD4+ T-Zellen-abhängiges MHC Major Mismatch aGvHD Mausmodell ein, um diese Zusammenhänge näher zu erforschen. Mittels Biolumineszenz-Bildgebung und dreidimensionale Lichtblattmikroskopie und Durchflusszytometrie-Analysen von früheren Zeitpunkten nach einer alloHCT bzw. im Anfangsstadium der aGvHD konnten wir zeigen, dass allogene T-Zellen exklusiv in die Milz, Lymphknoten und die Peyerschen Plaques migrieren und nicht in die intestinale Lamina propria. Indem wir transgene Mauslinien verwendeten, die keine oder eine nur partielle komplette hämatopoietische Antigenpräsentation aufwiesen, konnten wir eine sehr früh auf die alloHCT folgende allogene CD4+ T-Zellaktivierung in den lymphoiden Organen von MHCIIΔCD11c and MHCIIΔ Knochenmark-Chimären nachweisen. Aufgrund des, bei den MHCIIΔ Knochenmarks-Chimären auftretenden Versagens der negativen Thymusselektion und die daraus resultierende autoreaktive Immunreaktionen nach einer syngenen HCST stellte sich heraus, dass dies ein ungeeignetes Modell für die Untersuchung der Präsentation nicht-hämatopoetischer Antigene bei GvHD ist. Um diese Herausforderung zu bewältigen, generierten wir MHCIIΔVav1 Mäuse bei denen die MHC-Klasse-II-Expression auf allen hämatopoetischen Zellen fehlt. MHCIIΔVav1 Mäuse entwickelten eine aGvHD, wobei die Lymphknoten-Stromazellen dieser Tiere allogene CD4+ T-Zellen in gemischten Lymphozytenreaktionen aktivieren konnten. Ebenso konnten mesenteriale Lymphknoten von CD11c.DTR-Mäusen, die zuvor in eine MHCIIΔ Maus transplantiert wurden, CD4+ T-Zellen in vivo aktivieren, wodurch die Lymphknoten-Stromazellen eindeutig als nicht-hämatopoetische Antigen-präsentierende Zellen der lymphoiden Organe nachgewiesen werden konnten. Über das Cre/loxP-System konnten wir Knockout-Mäuse mit fehlender MHCII-Expression in Subpopulationen von Lymphknoten-Stromazellen generieren und verwendeten dann Einzelzell-RNA-Sequenzierung. Hier wählten wir Ccl19 und VE-Cadherin aus, um unsere Analyse spezifisch auf die fibroblastischen retikulären Zellen bzw. Endothelzellen der Lymphknoten zu konzentrieren. Bei MHCIIΔCcl19 Mäusen war die Aktivierung alloreaktiver CD4+ T-Zellen in der Initiationsphase der aGvHD mäßig reduziert, während das Fehlen von MHCII auf den fibroblastischen retikulären Zellen zu einer Hyperaktivierung allogener CD4+ T-Zellen führte, was wiederum eine schlechtere Überlebensrate der Mäuse zur Folge hatte. Dieser Phänotyp wurde durch regulatorische T-Zellen moduliert, die in der Lage waren, H2-Ab1fl Mäuse von den Folgen von GvHD zu retten, jedoch nicht die MHCIIΔCcl19. Ein Knock-out von MHCII auf Endothelzellen von MHCIIΔVE-Cadherin Mäusen, führte in der Initiationsphase der GvHD nur zu einer mäßig reduzierten Aktivierung von CD4+ T-Zellen. Umgekehrt zeigten MHCIIΔVE-Cadherin Mäuse im Langzeitüberleben jedoch einen protektiven Phänotyp verglichen mit wurfgeschwister H2-Ab1fl Mäusen. Um die Bedeutung der MHCII-Antigenpräsentation der Endothelzellen zu untersuchen, generierten wir außerdem MHCIIΔVE-CadherinΔVav1 Mäuse, bei welchen eine Antigenpräsentation, weder im endothelialen noch im hämatopoetischen Kompartiment möglich war. Lymphknoten-Stromazellen von MHCIIΔVE-CadherinΔVav1 Mäusen waren nicht in der Lage, alloreaktive CD4+ T-Zellen in einer gemischten Lymphozytenreaktion zu aktivieren. Insgesamt konnten wir zum ersten Mal beweisen, dass die MHC-Klassse II auf den Lymphknoten-Stromazellen eine entscheidende Rolle bei der Modulation allogener CD4+ T-Zellen in der Initiations- und schließlich in der Effektorphase der Graft-versus-Host-Disease spielt. N2 - In the initiation phase of acute graft-versus-host disease (aGvHD), CD4+ T cells are activated by hematopoietic antigen presenting cells in secondary lymphoid organs whereas in effector phase by non-hematopoietic cells in the small intestine. We hypothesized that alloreactive CD4+ T cells primarily home to the secondary lymphoid organs subsequent to allogeneic hematopoietic cell transplantation in the initiation phase of aGvHD and are activated by the non-hematopoietic lymph node stromal cells via MHC class II. To test this hypothesis, we employed CD4+ T cell-dependent major mismatch aGvHD mouse model to study this correlation. Upon analyzing the early events following allo-HCT with bioluminescence imaging, flow cytometry and whole-mount light sheet fluorescence microscopy, we found that allogeneic T cells exclusively home to the spleen, lymph nodes and the Peyer’s patches and not to the intestinal lamina propria in the initiation phase of aGvHD. Utilizing mice devoid of partial or complete hematopoietic antigen presentation we could show allogeneic CD4+ T cells activation in the lymphoid organs of MHCIIΔCD11c and MHCIIΔ BM chimeric mice early after allo-HCT. MHCIIΔ BM chimeras failure of thymic negative selection and developing tissue wasting disease upon syn-HCT deemed them unsuitable to study non-hematopoietic antigen presentation in aGvHD. To overcome this challenge, we generated MHCIIΔVav1 mice that lack MHC class II expression on all hematopoietic cells. MHCIIΔVav1 mice were susceptible to aGvHD and LNSCs from these animals activated allogeneic CD4+ T cells in mixed lymphocyte reaction. Likewise, mesenteric lymph nodes from CD11c.DTR mice surgically transplanted into a MHCIIΔ mouse could activate CD4+ T cells in vivo, clearly demonstrating LNSCs as non-hematopoietic APCs of the lymphoid organs. We specifically target lymph node stromal cell subsets via the Cre/loxP system, we employed single cell RNA sequencing and selected Ccl19 and VE-Cadherin to specifically target the fibroblastic reticular cells and endothelial cells of the lymph nodes respectively. In MHCIIΔCcl19 mice, alloreactive CD4+ T cells activation was discreetly reduced in the initiation phase of aGvHD whereas absence of MHCII on fibroblastic reticular cells resulted in hyper-activation of allogeneic CD4+ T cells leading to poor survival. This phenotype was modulated by the regulatory T cells that were able to rescue H2-Ab1fl mice but not the MHCIIΔCcl19 subsequent to GvHD. Knock-out of MHCII on endothelial cells MHCIIΔVE Cadherin, resulted only in modest reduction of CD4+ T cells activation in the initiation phase of GvHD, conversely MHCIIΔVE Cadherin mice showed a protective phenotype compared against littermates H2-Ab1fl mice in long-term survival. Furthermore, to pin-point endothelial cells MHCII antigen presentation we generated MHCIIΔVE Cadherin ΔVav1 animals devoid of antigen presentation in both endothelial and hematopoietic compartments. LNSCs from MHCIIΔVE Cadherin ΔVav1 were unable to activate alloreactive CD4+ T cells in mixed lymphocyte reaction. Altogether, we demonstrate for the first time that MHC class II on the lymph node stromal cells plays a crucial role in the modulation of allogeneic CD4+ T cells in the initiation and later in the effector phase of graft-versus-host-disease. KW - Transplantat-Wirt-Reaktion KW - Graft-versus-host disease KW - Hematopoietic cell transplantation KW - CD4+ T cell activation Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252015 ER - TY - JOUR A1 - Vargas, Juan Gamboa A1 - Wagner, Jennifer A1 - Shaikh, Haroon A1 - Lang, Isabell A1 - Medler, Juliane A1 - Anany, Mohamed A1 - Steinfatt, Tim A1 - Mosca, Josefina Peña A1 - Haack, Stephanie A1 - Dahlhoff, Julia A1 - Büttner-Herold, Maike A1 - Graf, Carolin A1 - Viera, Estibaliz Arellano A1 - Einsele, Hermann A1 - Wajant, Harald A1 - Beilhack, Andreas T1 - A TNFR2-Specific TNF fusion protein with improved in vivo activity JF - Frontiers in Immunology N2 - Tumor necrosis factor (TNF) receptor-2 (TNFR2) has attracted considerable interest as a target for immunotherapy. Indeed, using oligomeric fusion proteins of single chain-encoded TNFR2-specific TNF mutants (scTNF80), expansion of regulatory T cells and therapeutic activity could be demonstrated in various autoinflammatory diseases, including graft-versus-host disease (GvHD), experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). With the aim to improve the in vivo availability of TNFR2-specific TNF fusion proteins, we used here the neonatal Fc receptor (FcRn)-interacting IgG1 molecule as an oligomerizing building block and generated a new TNFR2 agonist with improved serum retention and superior in vivo activity. Methods Single-chain encoded murine TNF80 trimers (sc(mu)TNF80) were fused to the C-terminus of an in mice irrelevant IgG1 molecule carrying the N297A mutation which avoids/minimizes interaction with Fcγ-receptors (FcγRs). The fusion protein obtained (irrIgG1(N297A)-sc(mu)TNF80), termed NewSTAR2 (New selective TNF-based agonist of TNF receptor 2), was analyzed with respect to activity, productivity, serum retention and in vitro and in vivo activity. STAR2 (TNC-sc(mu)TNF80 or selective TNF-based agonist of TNF receptor 2), a well-established highly active nonameric TNFR2-specific variant, served as benchmark. NewSTAR2 was assessed in various in vitro and in vivo systems. Results STAR2 (TNC-sc(mu)TNF80) and NewSTAR2 (irrIgG1(N297A)-sc(mu)TNF80) revealed comparable in vitro activity. The novel domain architecture of NewSTAR2 significantly improved serum retention compared to STAR2, which correlated with efficient binding to FcRn. A single injection of NewSTAR2 enhanced regulatory T cell (Treg) suppressive activity and increased Treg numbers by > 300% in vivo 5 days after treatment. Treg numbers remained as high as 200% for about 10 days. Furthermore, a single in vivo treatment with NewSTAR2 upregulated the adenosine-regulating ectoenzyme CD39 and other activation markers on Tregs. TNFR2-stimulated Tregs proved to be more suppressive than unstimulated Tregs, reducing conventional T cell (Tcon) proliferation and expression of activation markers in vitro. Finally, singular preemptive NewSTAR2 administration five days before allogeneic hematopoietic cell transplantation (allo-HCT) protected mice from acute GvHD. Conclusions NewSTAR2 represents a next generation ligand-based TNFR2 agonist, which is efficiently produced, exhibits improved pharmacokinetic properties and high serum retention with superior in vivo activity exerting powerful protective effects against acute GvHD. KW - agonist KW - GvHD KW - regulatory T cells KW - serum retention KW - TNF KW - TNFR2 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-277436 SN - 1664-3224 VL - 13 ER - TY - JOUR A1 - Shaikh, Haroon A1 - Vargas, Juan Gamboa A1 - Mokhtari, Zeinab A1 - Jarick, Katja J. A1 - Ulbrich, Maria A1 - Mosca, Josefina Peña A1 - Viera, Estibaliz Arellano A1 - Graf, Caroline A1 - Le, Duc-Dung A1 - Heinze, Katrin G. A1 - Büttner-Herold, Maike A1 - Rosenwald, Andreas A1 - Pezoldt, Joern A1 - Huehn, Jochen A1 - Beilhack, Andreas T1 - Mesenteric Lymph Node Transplantation in Mice to Study Immune Responses of the Gastrointestinal Tract JF - Frontiers in Immunology N2 - Mesenteric lymph nodes (mLNs) are sentinel sites of enteral immunosurveillance and immune homeostasis. Immune cells from the gastrointestinal tract (GIT) are constantly recruited to the mLNs in steady-state and under inflammatory conditions resulting in the induction of tolerance and immune cells activation, respectively. Surgical dissection and transplantation of lymph nodes (LN) is a technique that has supported seminal work to study LN function and is useful to investigate resident stromal and endothelial cell biology and their cellular interactions in experimental disease models. Here, we provide a detailed protocol of syngeneic mLN transplantation and report assays to analyze effective mLN engraftment in congenic recipients. Transplanted mLNs allow to study T cell activation and proliferation in preclinical mouse models. Donor mLNs proved viable and functional after surgical transplantation and regenerated blood and lymphatic vessels. Immune cells from the host completely colonized the transplanted mLNs within 7-8 weeks after the surgical intervention. After allogeneic hematopoietic cell transplantation (allo-HCT), adoptively transferred allogeneic CD4+ T cells from FVB/N (H-2q) mice homed to the transplanted mLNs in C57BL/6 (H-2b) recipients during the initiation phase of acute graft-versus-host disease (aGvHD). These CD4+ T cells retained full proliferative capacity and upregulated effector and gut homing molecules comparable to those in mLNs from unmanipulated wild-type recipients. Wild type mLNs transplanted into MHCII deficient syngeneic hosts sufficed to activate alloreactive T cells upon allogeneic hematopoietic cell transplantation, even in the absence of MHCII+ CD11c+ myeloid cells. These data support that orthotopically transplanted mLNs maintain physiological functions after transplantation. The technique of LN transplantation can be applied to study migratory and resident cell compartment interactions in mLNs as well as immune reactions from and to the gut under inflammatory and non-inflammatory conditions. KW - acute graft-versus host disease KW - alloreactive T cells KW - mesenteric lymph node KW - lymph node transplantation KW - mouse models KW - lymph node stromal cells Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-244869 SN - 1664-3224 VL - 12 ER - TY - JOUR A1 - Jarick, Katja J. A1 - Mokhtari, Zeinab A1 - Scheller, Lukas A1 - Hartweg, Julia A1 - Thusek, Sina A1 - Le, Duc-Dung A1 - Ranecky, Maria A1 - Shaikh, Haroon A1 - Qureischi, Musga A1 - Heinze, Katrin G. A1 - Beilhack, Andreas T1 - Photoconversion of Alloreactive T Cells in Murine Peyer’s Patches During Acute Graft-Versus-Host Disease: Tracking the Homing Route of Highly Proliferative Cells In Vivo JF - Frontiers in Immunology N2 - The regulation of immune cell migration throughout the body is essential to warrant immunosurveillance and to maintain immune homeostasis. Marking and tracking of these cells has proven important to study mechanisms of immune cell trafficking and cell interaction in vivo. Photoconversion is a well-suited technique for intravital application because it enables contactless time- and location-specific marking of cells in the tissue without surgically manipulating the microenvironment of the cells in question. However, in dividing cells the converted fluorescent protein may decline quickly. Here, we provide a detailed description of the photoconversion technique and its applicability to tracking highly proliferating T cells from the priming site of T cell activation to peripheral target organs of effector function in a preclinical model. Dendra2+ T cells were photoconverted in the Peyer’s patches during the initiation phase of acute graft-versus-host disease (GvHD) and tracked through the mesenteric lymph nodes and the peripheral blood to the small intestine with flow cytometry and intravital two-photon microscopy. Photoconverted alloreactive T cells preserved the full proliferative capacity, homing, and migration of alloreactive T cells in the intestinal lamina propria. We conclusively proved that photoconversion of highly proliferative alloreactive T cells in the Peyer’s patches is an effective tool to study trafficking of alloreactive T cells under physiologic conditions and to GvHD target tissues. This technique can also be applied to the study of immune cell tracking under inflammatory and non-inflammatory conditions. KW - T cell migration KW - acute graft-versus-host disease KW - mouse models KW - photoconversion KW - Dendra2 KW - Peyer's patch KW - in vivo cell tracking KW - lymphocyte homing Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-323309 VL - 9 ER -